After 2 years of experience with tisagenlecleucel, relapse after cellular immunotherapy is emerging as a new therapeutic challenge.29 Relapses after CAR-T cell failure, especially CD19 negative relapses, and relapsed/refractory T cell ALL should be considered/screened for the SeluDex trial. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.